NOXXON Pharma is a biotechnology company developing a promising new class of therapeutics called Spiegelmers, which are oligonucleotides made from the L-stereoisomer of RNA. Spiegelmers can be engineered to bind specifically to a precisely defined biological target and have been shown to be potent inhibitors. Clinical and pre-clinical studies of Spiegelmers to date have shown them to be exceptionally safe, well-tolerated, biologically stable and non-immunogenic. NOXXON has three programs in development, two of which have successfully completed their first Phase I clinical studies. The company has approximately 60 employees based at its headquarter in Berlin, Germany.

Marktsegmente

Rote Biotechnologie, Rote Biotechnologie - Medikamente und Drug Delivery, Rote Biotechnologie - Technologie und Dienstleistungen für Medikamentenentwicklung